Table 4.

Summary of cancer-related adverse events in the entire study cohort and patients with malignancy at baseline enrolled in the Trial to Reduce Cardiovascular Events with Aranesp Therapy

EventsDarbepoietin (n=2012)Placebo (n=2026)P value
Cancer–related adverse event139 (6.9%)134 (6.4%)0.53
Cancer-related deaths39 (1.9%)25 (1.2%)0.08
Malignancy at baseline, n188160
 All-cause mortality60 (32%)37 (23%)0.13
 Cancer-related deaths14 (2.4%)1 (0.6%)0.002